安进Amgen Inc. (AMGN) 2013年年度报告「NASDAQ」.pdf

1、Dear Shareholders,2013 was a landmark year for Amgen.We delivered financially for investors as we executed on our core strategies and set the stage for long-term growth.In 2013,revenues increased 8 percent to$18.7 billion.Adjusted earnings per share*grew 17 percent to$7.60,reflecting strong executio

2、n and continued momentum in our business.Our total shareholder return of 35 percent outperformed the S&P 500 in 2013.Just as important,we made the long-term investments necessary to continue to advance our later-stage pipeline and grow globally.We plan to have pivotal data on 10 innovative molecules

3、 in our later-stage pipeline by 2016 and to advance a portfolio of six biosimilar molecules that have the potential to begin launching in 2017.We are also now present in more than 75 countries,including Japan,China and other emerging markets.All of this gives me great confidence that we are creating

4、 a very exciting future for Amgen.We are pushing the boundaries of biotechnology to find new ways to deliver for patients suffering from serious illnesses.We are also bringing our medicines to new markets,providing new treatment options for patients around the world.Delivering for ShareholdersConsis

5、tent with our capital allocation strategy,we continued to return significant capital to shareholders:first,in the form of$1.4 billion in cash dividends paid in 2013,and second,through the repurchase of$0.8 billion of our stock in 2013,for a total return of capital of$2.2 billion.In December 2013,we

6、declared a dividend of$0.61 per share of common stock,payable in March 2014,representing a 30 percent increase over the quarterly dividend paid in each of the last four quarters.In addition to a higher dividend,our share price appreciated significantly in 2013.Continued Product GrowthOur performance